{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:37:22Z","timestamp":1781710642448,"version":"3.54.5"},"reference-count":77,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jdiacomp.2020.107811","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T12:39:45Z","timestamp":1606394385000},"page":"107811","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["The role of sodium glucose co-transporter inhibitors in heart failure prevention"],"prefix":"10.1016","volume":"35","author":[{"given":"Vishnu","family":"Garla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Subauste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian F.","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107811_bb0005","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jacc.2018.01.047","article-title":"Prevalent and incident heart failure in cardiovascular outcome trials of patients with type 2 diabetes","volume":"71","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0025","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0030","author":"International Diabetes Federation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0035","author":"Centers for Disease Control and Prevention"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0040","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0045","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1001\/jama.1979.03290450033020","article-title":"Diabetes and cardiovascular disease: the Framingham study","volume":"241","author":"Kannel","year":"1979","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0050","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2337\/dc08-1709","article-title":"Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program","volume":"32","author":"Preiss","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0055","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.2337\/dc10-0286","article-title":"Diabetes, glycemic control, and new-onset heart failure in patients with stable coronary artery disease: data from the heart and soul study","volume":"33","author":"van Melle","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0060","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1161\/01.CIR.103.22.2668","article-title":"Glycemic control and heart failure among adult patients with diabetes","volume":"103","author":"Iribarren","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0065","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1093\/eurjhf\/hfs067","article-title":"Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"14","author":"Preiss","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0070","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","article-title":"Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme","volume":"29","author":"MacDonald","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0075","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1002\/phar.1853","article-title":"Positive impact of continuous-flow left ventricular assist device implantation on glycemic control in patients with type 2 diabetes mellitus and advanced chronic systolic heart failure","volume":"36","author":"Yen","year":"2016","journal-title":"Pharmacotherapy."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0080","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1800256","article-title":"Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes","volume":"379","author":"Rawshani","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2337\/diacare.27.3.699","article-title":"Heart failure prevalence, incidence, and mortality in the elderly with diabetes","volume":"27","author":"Bertoni","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1475-2840-1-1","article-title":"How hyperglycemia promotes atherosclerosis: molecular mechanisms","volume":"1","author":"Aronson","year":"2002","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0095","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJM198805193182007","article-title":"Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications","volume":"318","author":"Brownlee","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0105","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.phrs.2016.12.016","article-title":"Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications","volume":"116","author":"Qin","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0110","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis","volume":"39","author":"Mudaliar","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1172\/JCI0214080","article-title":"The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus","volume":"109","author":"Finck","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0120","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1172\/JCI117823","article-title":"Glycemic improvement in diabetic db\/db mice by overexpression of the human insulin-regulatable glucose transporter (GLUT4)","volume":"95","author":"Gibbs","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0125","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1152\/physrev.00006.2004","article-title":"Myocardial substrate metabolism in the normal and failing heart","volume":"85","author":"Stanley","year":"2005","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.yjmcc.2008.06.009","article-title":"PARP mediates structural alterations in diabetic cardiomyopathy","volume":"45","author":"Chiu","year":"2008","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0135","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s00395-008-0715-2","article-title":"Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy","volume":"103","author":"Van Linthout","year":"2008","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12974-019-1498-0","article-title":"NLRP3 inflammasome as a potential treatment in ischemic stroke concomitant with diabetes","volume":"16","author":"Hong","year":"2019","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0145","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0150","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nrendo.2015.216","article-title":"Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy","volume":"12","author":"Jia","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0155","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.yjmcc.2017.02.004","article-title":"Membrane potential determines calcium alternans through modulation of SR Ca2+ load and L-type Ca2+ current","volume":"105","author":"Kanaporis","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0160","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.2337\/diabetes.53.12.3201","article-title":"Decreased sarcoplasmic reticulum activity and contractility in diabetic db\/db mouse heart","volume":"53","author":"Belke","year":"2004","journal-title":"Diabetes."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0165","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/CIRCULATIONAHA.112.120402","article-title":"Association between coronary vascular dysfunction and cardiac mortality in patients with and without diabetes mellitus","volume":"126","author":"Murthy","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0170","doi-asserted-by":"crossref","DOI":"10.1111\/micc.12340","article-title":"Current perspectives in coronary microvascular dysfunction","volume":"24","author":"Shome","year":"2017","journal-title":"Microcirculation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0175","doi-asserted-by":"crossref","first-page":"H118","DOI":"10.1152\/ajpheart.00932.2010","article-title":"Increased propensity for cell death in diabetic human heart is mediated by mitochondrial-dependent pathways","volume":"300","author":"Anderson","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0180","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1172\/JCI100559","article-title":"The action of phlorizin on the excretion of glucose, xylose, sucrose, creatinine and urea by man","volume":"12","author":"Chasis","year":"1933","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0185","series-title":"Drug approval package: Invokana (canagliflozin) tablets NDA #204042","year":"1999"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0190","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0195","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/cvr\/cvx149","article-title":"Cardiac effects of SGLT2 inhibitors: the sodium hypothesis","volume":"114","author":"Bertero","year":"2018","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0200","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0205","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/dom.13126","article-title":"Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis","volume":"20","author":"Hallow","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0210","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.007046","article-title":"Interaction between the sodium-glucose-linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects","volume":"7","author":"Wilcox","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0215","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/dc16-0041","article-title":"SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study","volume":"39","author":"Abdul-Ghani","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0220","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2174\/1570161116666180831124717","article-title":"Resistance to diuretics in heart failure: any role for empagliflozin?","volume":"17","author":"Katsiki","year":"2019","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0225","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lfs.2018.01.032","article-title":"The anti-diabetic drug dapagliflozin induces vasodilation via activation of PKG and Kv channels","volume":"197","author":"Li","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0230","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-020-00997-7","article-title":"Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat","volume":"19","author":"Park","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0235","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0240","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0245","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0250","doi-asserted-by":"crossref","first-page":"107408","DOI":"10.1016\/j.jdiacomp.2019.07.005","article-title":"Iron absorption, bone marrow fat and hematopoiesis in heart failure: additional mechanisms of action for sodium-glucose co-transporter 2 inhibitors (SGLT2i)?","volume":"33","author":"Katsiki","year":"2019","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0255","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0260","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0265","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","article-title":"The diabetic heart utilizes ketone bodies as an energy source","volume":"77","author":"Mizuno","year":"2017","journal-title":"Metabolism"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0270","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cmet.2016.07.018","article-title":"Empagliflozin\u2019s fuel hypothesis: not so soon","volume":"24","author":"Lopaschuk","year":"2016","journal-title":"Cell Metab"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0275","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1073\/pnas.1016088108","article-title":"Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41)","volume":"108","author":"Kimura","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0280","first-page":"S169","article-title":"Direct effects of empagliflozin on extracellular matrix remodeling in human cardiac fibroblasts: novel translational clues to EMPA-REG outcome","volume":"33","author":"Kang","year":"2017","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0285","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/dom.13229","article-title":"Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis","volume":"20","author":"Packer","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0290","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.metabol.2018.02.002","article-title":"Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes","volume":"85","author":"Garvey","year":"2018","journal-title":"Metabolism."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0295","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13098-017-0275-4","article-title":"Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus","volume":"9","author":"Yagi","year":"2017","journal-title":"Diabetol Metab Syndr"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0300","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0305","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0310","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+\/H+ exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0315","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0320","author":"Food and Drug Administration"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0325","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/CIRCULATIONAHA.119.042155","article-title":"Heart failure end points in cardiovascular outcome trials of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a critical evaluation of clinical and regulatory issues","volume":"140","author":"Butler","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0330","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.tcm.2016.07.008","article-title":"Impact of empagliflozin in patients with diabetes and heart failure","volume":"27","author":"Pham","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0335","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0340","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.117.032038","article-title":"Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"137","author":"Mahaffey","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0345","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0350","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","article-title":"Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus","volume":"139","author":"Kato","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0355","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12933-019-0919-9","article-title":"Comparative risk evaluation for cardiovascular events associated with dapagliflozin vs. empagliflozin in real-world type 2 diabetes patients: a multi-institutional cohort study","volume":"18","author":"Shao","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0360","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/dom.13805","article-title":"Do GLP-1RAs and SGLT-2is reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis","volume":"21","author":"Mishriky","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0365","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0370","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2018.01.085","article-title":"SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL","volume":"71","author":"Cavender","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0375","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-019-0938-6","article-title":"Lessons learned from the DAPA-HF trial concerning the mechanisms of benefit of SGLT2 inhibitors on heart failure events in the context of other large-scale trials nearing completion","volume":"18","author":"Packer","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0380","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107811_bb0385","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/dme.14140","article-title":"Treatment of heart failure with sodium glucose co-transporter-2 inhibitors in people with type 2 diabetes mellitus: current evidence and future directions","volume":"36","author":"Sharma","year":"2019","journal-title":"Diabet Med"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272030605X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105687272030605X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:12:34Z","timestamp":1761005554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105687272030605X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":77,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S105687272030605X"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107811","relation":{},"ISSN":["1056-8727"],"issn-type":[{"value":"1056-8727","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of sodium glucose co-transporter inhibitors in heart failure prevention","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107811","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107811"}}